Clinical Trial

A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

Study acronym: DURAFAK
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or solid gynecological cancer.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-08-19; most recent amendment 2025-10-20.
Status change: Not Yet Recruiting → Recruiting 2023-02-27
Trial Details
NCT Number NCT05512208
Lead Sponsor University of Oklahoma
Collaborators: Verastem, Inc.
Conditions Endometrioid Cancer, Mucinous Ovarian Cancer, High Grade Serous Ovarian Cancer, Cervical Cancer, Solid Tumor
Enrollment 55 participants
Start Date 2023-02-06
Primary Completion 2027-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2025-10-22